Answer
Patients of childbearing potential should use effective contraception throughout mirvetuximab soravtansine treatment and for 7 months after the last dose.
Sources for this answer
- ELAHERE 5 mg/mL concentrate for solution for infusionAbbVie Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked